Not Tagged
gilead
['gilead']
as #asco23 draws to a close, frank neumann, senior vice president, global head of clinical development at kite, provides insight on the importance of overall survival data in cancer clinical trials.
The impossible is not impossible. It’s simply what hasn’t been achieved yet. Twitter guidelines: https://t.co/vWkdtfUf7N